摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-pyridylmethylthio)-N-(6-quinolyl)pyridine-3-carboxamide

中文名称
——
中文别名
——
英文名称
2-(4-pyridylmethylthio)-N-(6-quinolyl)pyridine-3-carboxamide
英文别名
2-(pyridin-4-ylmethylsulfanyl)-N-quinolin-6-ylpyridine-3-carboxamide
2-(4-pyridylmethylthio)-N-(6-quinolyl)pyridine-3-carboxamide化学式
CAS
——
化学式
C21H16N4OS
mdl
——
分子量
372.45
InChiKey
ZDYGLPLQBXMIJN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    27
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    93.1
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • Novel compounds having 4-pyridylalkylthio group as substituent
    申请人:Honda Takahiro
    公开号:US20060194836A1
    公开(公告)日:2006-08-31
    A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases in which angiogenesis or augmentation of vascular permeability is involved. In the formula, ring “A” is a benzene ring or an aromatic five- or six-memberd heterocycle which can be fused with a cycloalkane ring, “B” is alkylene, R 1 and R 2 , the same or different, are H, OH, substituted or unsubstituted alkoxy and the like, X and Y, the same or different, are group(s) selected from H, halogen, OH, substituted or unsubstituted alkoxy and the like respectively, p is 0, 1 or 2, and q is 0 or 1.
    本发明的目的是提供一种新的芳香性五元或六元杂环衍生物,其具有4-吡啶基烷硫基取代基或其盐,可作为药物使用。以下通式[I]所表示的化合物或其盐可用作治疗涉及血管生成或增强血管渗透性的疾病的治疗剂。其中,环“A”是苯环或芳香性五元或六元杂环,可以与环状烷基环融合,“B”是烷基,R1和R2,相同或不同,是H、OH、取代或未取代的烷氧基等,X和Y,相同或不同,分别是选择自H、卤素、OH、取代或未取代的烷氧基等的基团,p为0、1或2,q为0或1。
  • Compounds having a 4-pyridylalkylthio group as a substituent
    申请人:Honda Takahiro
    公开号:US20090286786A1
    公开(公告)日:2009-11-19
    A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is benzene or an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R 1 and R 2 are hydrogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R 1 and R 2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.
    一种具有以下式[I]或其药学上可接受的盐的化合物:其中,A是苯或一种芳香五元杂环,该芳香五元杂环可以选择性地与环烷环融合;B是一种烷基;R1和R2是氢、羟基、烷氧基、芳基氧基、烷基、环烷基、芳基、杂环、氨基、烷基氨基、芳基氨基或酰基,或R1和R2结合形成一个杂环;X和Y是氢、卤素、羟基、烷氧基、芳基氧基、烷基、环烷基、芳基、巯基、烷硫基、芳硫基、羧基、羧酸酯、羧酰胺、氰基或硝基;p为0、1或2;q为0或1。该化合物用于治疗与血管生成或血管通透性增加有关的疾病。
  • COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT
    申请人:Honda Takahiro
    公开号:US20120202817A1
    公开(公告)日:2012-08-09
    A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R 1 and R 2 are hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R 1 and R 2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.
    以下化合物式[I]或其药学上可接受的盐:其中A是一种芳香五元杂环,可选择与环烷基融合;B是一种烷基;R1和R2是氢、羟基、烷氧基、芳氧基、烷基、环烷基、芳基、杂环、氨基、烷基氨基、芳基氨基或酰基,或R1和R2结合形成一个杂环;X和Y是氢、卤素、羟基、烷氧基、芳氧基、烷基、环烷基、芳基、巯基、烷硫基、芳硫基、羧基、羧酸酯、羧酰胺、氰基或硝基;p为0、1或2;q为0或1。该化合物可用于治疗涉及血管生成或增强血管通透性的疾病。
  • NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT
    申请人:SANTEN PHARMACEUTICAL CO., LTD.
    公开号:EP1602647B1
    公开(公告)日:2013-10-16
  • US7534802B2
    申请人:——
    公开号:US7534802B2
    公开(公告)日:2009-05-19
查看更多